{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:33:04Z","timestamp":1694633584288},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2008,9,24]],"date-time":"2008-09-24T00:00:00Z","timestamp":1222214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s10585-008-9212-0","type":"journal-article","created":{"date-parts":[[2008,9,23]],"date-time":"2008-09-23T21:07:08Z","timestamp":1222204028000},"page":"903-911","source":"Crossref","is-referenced-by-count":7,"title":["Inhibition of osteolytic bone metastasis by unfractionated heparin"],"prefix":"10.1007","volume":"25","author":[{"given":"Colin K.","family":"Yee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melec","family":"Zeadin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen G.","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,24]]},"reference":[{"key":"9212_CR1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584\u2013593. doi: 10.1038\/nrc867","journal-title":"Nat Rev Cancer"},{"key":"9212_CR2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0748-7983(95)95176-8","volume":"21","author":"NJ Carty","year":"1995","unstructured":"Carty NJ, Foggitt A, Hamilton CR et al (1995) Patterns of clinical metastasis in breast cancer: an analysis of 100 patients. Eur J Surg Oncol 21:607\u2013608. doi: 10.1016\/S0748-7983(95)95176-8","journal-title":"Eur J Surg Oncol"},{"key":"9212_CR3","first-page":"4122","volume":"7","author":"B Naume","year":"2001","unstructured":"Naume B, Borgen E, Kvalheim G et al (2001) Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin Cancer Res 7:4122\u20134129","journal-title":"Clin Cancer Res"},{"key":"9212_CR4","first-page":"1884","volume":"63","author":"B Taback","year":"2003","unstructured":"Taback B, Giuliano AE, Hansen NM et al (2003) Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients. Cancer Res 63:1884\u20131887","journal-title":"Cancer Res"},{"key":"9212_CR5","first-page":"885","volume":"6","author":"AK Kakkar","year":"1995","unstructured":"Kakkar AK, Hedges AR, Williamson RCN (1995) Perioperative heparin therapy inhibits late deaths from metastatic cancer. Int J Oncol 6:885\u2013888","journal-title":"Int J Oncol"},{"key":"9212_CR6","doi-asserted-by":"crossref","unstructured":"Lebeau B, Chastang C, Brechot JM et\u00a0al (1994) Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer 74:38\u201345. doi :10.1002\/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E","DOI":"10.1002\/1097-0142(19940701)74:1<38::AID-CNCR2820740108>3.0.CO;2-E"},{"key":"9212_CR7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","volume":"339","author":"P Prandoni","year":"1992","unstructured":"Prandoni P, Lensing AWA, Buller HR (1992) Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339:441\u2013445. doi: 10.1016\/0140-6736(92)91054-C","journal-title":"Lancet"},{"key":"9212_CR8","first-page":"815","volume":"16","author":"GF Tempelhoff von","year":"2000","unstructured":"von Tempelhoff GF, Harenberg J, Niemann F (2000) Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized double-blind trial. Int J Oncol 16:815\u2013824","journal-title":"Int J Oncol"},{"key":"9212_CR9","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","volume":"2","author":"M Altinbas","year":"2004","unstructured":"Altinbas M, Coskun HS, Er O et al (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2:1266\u20131271. doi: 10.1111\/j.1538-7836.2004.00871.x","journal-title":"J Thromb Haemost"},{"key":"9212_CR10","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1200\/JCO.2004.10.002","volume":"22","author":"AK Kakkar","year":"2004","unstructured":"Kakkar AK, Levine MN, Kadziola Z (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944\u20131948. doi: 10.1200\/JCO.2004.10.002","journal-title":"J Clin Oncol"},{"key":"9212_CR11","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0037-1616771","volume":"86","author":"SM Smorenburg","year":"2001","unstructured":"Smorenburg SM, Vink R, Otten HM (2001) The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 86:1586\u20131587","journal-title":"Thromb Haemost"},{"key":"9212_CR12","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Warkentin TE, Shaughnessy SG et al (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 119:64S\u201394S. doi: 10.1378\/chest.119.1_suppl.64S","journal-title":"Chest"},{"key":"9212_CR13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1039\/b100916h","volume":"19","author":"DL Rabenstein","year":"2002","unstructured":"Rabenstein DL (2002) Heparin and heparan sulfate: structure and function. Nat Prod Rep 19:312\u2013331. doi: 10.1039\/b100916h","journal-title":"Nat Prod Rep"},{"key":"9212_CR14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/glycob\/8.2.131","volume":"8","author":"HA Harrop","year":"1998","unstructured":"Harrop HA, Rider CC (1998) Heparin and its derivatives bind to HIV-1 recombinant envelope glycoproteins, rather than to recombinant HIV-1 receptor, CD4. Glycobiology 8:131\u2013137. doi: 10.1093\/glycob\/8.2.131","journal-title":"Glycobiology"},{"key":"9212_CR15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF02592355","volume":"26","author":"AL Howell","year":"1996","unstructured":"Howell AL, Taylor TH, Miller JD et al (1996) Inhibition of HIV-1 infectivity by low molecular weight heparin. Results of in\u00a0vitro studies and a pilot clinical trial in patients with advanced AIDS. Int J Clin Lab Res 26:124. doi: 10.1007\/BF02592355","journal-title":"Int J Clin Lab Res"},{"key":"9212_CR16","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V82.11.3253.3253","volume":"82","author":"RM Nelson","year":"1993","unstructured":"Nelson RM, Cecconi O, Roberts WG et al (1993) Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 82:3253\u20133258","journal-title":"Blood"},{"key":"9212_CR17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1054-3589(08)60471-8","volume":"46","author":"DJ Tyrrell","year":"1999","unstructured":"Tyrrell DJ, Horne AP, Holme KR et al (1999) Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 46:151\u2013208. doi: 10.1016\/S1054-3589(08)60471-8","journal-title":"Adv Pharmacol"},{"key":"9212_CR18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V88.4.1314.bloodjournal8841314","volume":"88","author":"JM Muir","year":"1996","unstructured":"Muir JM, Andrew M, Hirsh J et al (1996) Histomorphometric analysis of the effects of standard heparin on trabecular bone in\u00a0vivo. Blood 88:1314\u20131320","journal-title":"Blood"},{"key":"9212_CR19","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood.V89.9.3236","volume":"89","author":"JM Muir","year":"1997","unstructured":"Muir JM, Hirsh J, Weitz JI et al (1997) A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 89:3236\u20133242","journal-title":"Blood"},{"key":"9212_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00316875","volume":"51","author":"TA Einhorn","year":"1992","unstructured":"Einhorn TA (1992) Bone strength: the bottom line. Calcif Tissue 51:333\u2013339. doi: 10.1007\/BF00316875","journal-title":"Calcif Tissue"},{"key":"9212_CR21","first-page":"39","volume-title":"Primer on the metabolic bone diseases and disorders of mineral","author":"CT Rubin","year":"1999","unstructured":"Rubin CT, Rubin J (1999) Biomechanics of bone. In: Favus M (ed) Primer on the metabolic bone diseases and disorders of mineral. Lippincott, Williams and Wilkins, Philadelphia, pp 39\u201342"},{"key":"9212_CR22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH05-07-0515","volume":"95","author":"RJ Ludwig","year":"2006","unstructured":"Ludwig RJ, Alban S, Bistrian R et al (2006) The ability of different forms of heparins to suppress P-selectin function in\u00a0vitro correlates to their inhibitory capacity on bloodborne metastasis in\u00a0vivo. Thromb Haemost 95:535\u2013540","journal-title":"Thromb Haemost"},{"key":"9212_CR23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10585-005-3859-6","volume":"22","author":"B Bereczky","year":"2005","unstructured":"Bereczky B, Gilly R, Raso E et al (2005) Selective antimetastatic effect of heparins in preclinical human melanoma models is based on inhibition of migration and microvascular arrest. Clin Exp Metastasis 22:69\u201376. doi: 10.1007\/s10585-005-3859-6","journal-title":"Clin Exp Metastasis"},{"key":"9212_CR24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1160\/TH06-05-0289","volume":"96","author":"SA Mousa","year":"2006","unstructured":"Mousa SA, Lindhardt R, Francis JL et al (2006) Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 96:816\u2013821","journal-title":"Thromb Haemost"},{"key":"9212_CR25","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-03-1054","volume":"64","author":"RJ Ludwig","year":"2004","unstructured":"Ludwig RJ, Boehme B, Podda M et al (2004) Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 64:2743\u20132750. doi: 10.1158\/0008-5472.CAN-03-1054","journal-title":"Cancer Res"},{"key":"9212_CR26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","volume":"25","author":"JR Canon","year":"2008","unstructured":"Canon JR, Roudier M, Bryant R et al (2008) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25:119\u2013129. doi: 10.1007\/s10585-007-9127-1","journal-title":"Clin Exp Metastasis"},{"key":"9212_CR27","first-page":"4432","volume":"61","author":"S Morony","year":"2001","unstructured":"Morony S, Capparelli C, Sarosi I et al (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61:4432\u20134436","journal-title":"Cancer Res"},{"key":"9212_CR28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","volume":"107","author":"J Zhang","year":"2001","unstructured":"Zhang J, Dai J, Qi Y et al (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235\u20131244. doi: 10.1172\/JCI11685","journal-title":"J Clin Invest"},{"key":"9212_CR29","doi-asserted-by":"crossref","unstructured":"Yoneda T, Michigami T, Yi B et\u00a0al (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88:2979\u20132988. doi :10.1002\/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U","DOI":"10.1002\/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U"},{"key":"9212_CR30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10585-006-9008-z","volume":"23","author":"SH Tannehill-Gregg","year":"2006","unstructured":"Tannehill-Gregg SH, Levine AL, Nadella MVP et al (2006) The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 23:19\u201331. doi: 10.1007\/s10585-006-9008-z","journal-title":"Clin Exp Metastasis"},{"key":"9212_CR31","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood.V86.4.1368.bloodjournal8641368","volume":"86","author":"SG Shaughnessy","year":"1995","unstructured":"Shaughnessy SG, Young E, Deschamps P et al (1995) The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:1368\u20131373","journal-title":"Blood"},{"key":"9212_CR32","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1055\/s-0037-1615384","volume":"80","author":"C Shigemori","year":"1998","unstructured":"Shigemori C, Wada H, Matsumoto K et al (1998) Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 80:894\u2013898","journal-title":"Thromb Haemost"},{"key":"9212_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.pai.0000213157.94804.fc","volume":"16","author":"V Kaushal","year":"2008","unstructured":"Kaushal V, Mukunyadzi P, Siegel ER et al (2008) Expression of tissue factor in prostate cancer correlates with malignant phenotype. Appl Immunohistochem Mol Morphol 16:1\u20136","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"9212_CR34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1054\/bjoc.2000.1272","volume":"83","author":"T Ueno","year":"2000","unstructured":"Ueno T, Toi M, Koike M et al (2000) Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 83:164\u2013170. doi: 10.1054\/bjoc.2000.1272","journal-title":"Br J Cancer"},{"key":"9212_CR35","doi-asserted-by":"crossref","first-page":"11832","DOI":"10.1073\/pnas.89.24.11832","volume":"89","author":"BM Mueller","year":"1992","unstructured":"Mueller BM, Reisfeld RA, Edgington TS et al (1992) Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89:11832\u201311836. doi: 10.1073\/pnas.89.24.11832","journal-title":"Proc Natl Acad Sci USA"},{"key":"9212_CR36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2004-02-0434","volume":"104","author":"E Camerer","year":"2005","unstructured":"Camerer E, Qazi AA, Duong DN et al (2005) Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104:397\u2013401. doi: 10.1182\/blood-2004-02-0434","journal-title":"Blood"},{"key":"9212_CR37","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1172\/JCI113411","volume":"81","author":"S Karpatikin","year":"1988","unstructured":"Karpatikin S, Pearlstein E, Ambrogio C et al (1988) Role of adhesive proteins in platelet tumor interaction in\u00a0vitro and metastasis formation in\u00a0vivo. J Clin Invest 81:1012\u20131019. doi: 10.1172\/JCI113411","journal-title":"J Clin Invest"},{"key":"9212_CR38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03032368","volume":"6","author":"SA Cohen","year":"2000","unstructured":"Cohen SA, Trikha M, Mascelli MA (2000) Potential future clinical applications for the GPIIb\/IIIa antagonist, abciximab in thrombosis, vascular oncological indications. Pathol Oncol Res 6:163\u2013174","journal-title":"Pathol Oncol Res"},{"key":"9212_CR39","first-page":"549","volume":"90","author":"A Amirkhosravi","year":"2004","unstructured":"Amirkhosravi A, Mousa SA, Amaya M et al (2004) Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GPIIb\/IIIa antagonist XV454. Thromb Haemost 90:549\u2013554","journal-title":"Thromb Haemost"},{"key":"9212_CR40","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/1078-0432.CCR-05-1131","volume":"11","author":"JL Stevenson","year":"2005","unstructured":"Stevenson JL, Choi SH, Varki A (2005) Differential metastasis inhibition by clinically relevant levels of heparins\u2014correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 11:7003\u20137011. doi: 10.1158\/1078-0432.CCR-05-1131","journal-title":"Clin Cancer Res"},{"key":"9212_CR41","first-page":"16","volume":"19","author":"L Borsig","year":"2004","unstructured":"Borsig L (2004) Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol Sci 19:16\u201321. doi: 10.1152\/nips.01450.2003","journal-title":"News Physiol Sci"},{"key":"9212_CR42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1023\/A:1018532409041","volume":"14","author":"R Kannagi","year":"1997","unstructured":"Kannagi R (1997) Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J 14:577\u2013584. doi: 10.1023\/A:1018532409041","journal-title":"Glycoconj J"},{"key":"9212_CR43","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.061615598","volume":"98","author":"L Borsig","year":"2001","unstructured":"Borsig L, Wong R, Feramisco J et al (2001) Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins and tumor metastasis. Proc Natl Acad Sci USA 98:3352\u20133357. doi: 10.1073\/pnas.061615598","journal-title":"Proc Natl Acad Sci USA"},{"key":"9212_CR44","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.febslet.2007.01.005","volume":"581","author":"M Takita","year":"2007","unstructured":"Takita M, Inada M, Maruyama T et al (2007) Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells. FEBS Lett 581:565\u2013571. doi: 10.1016\/j.febslet.2007.01.005","journal-title":"FEBS Lett"},{"key":"9212_CR45","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.2234372100","volume":"100","author":"SJ Bakewell","year":"2003","unstructured":"Bakewell SJ, Nestor P, Prasad S et al (2003) Platelet and osteoclast \u03b23 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 100:14205\u201314210. doi: 10.1073\/pnas.2234372100","journal-title":"Proc Natl Acad Sci USA"},{"key":"9212_CR46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0038-1642376","volume":"71","author":"M Monreal","year":"1994","unstructured":"Monreal M, Lafoz E, Olive A, del Rio L, Vedia C (1994) Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to Coumarin. Thromb Haemost 71:7\u201311","journal-title":"Thromb Haemost"},{"key":"9212_CR47","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0037-1612970","volume":"87","author":"V Pettila","year":"2002","unstructured":"Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R (2002) Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87:182\u2013196","journal-title":"Thromb Haemost"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-008-9212-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-008-9212-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-008-9212-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T01:37:50Z","timestamp":1631842670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-008-9212-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,24]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["9212"],"URL":"https:\/\/doi.org\/10.1007\/s10585-008-9212-0","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,24]]}}}